Kiora Pharmaceuticals Valuation
| KPRX Stock | USD 2.12 0.07 3.20% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Kiora Pharmaceuticals secures a last-minute Real Value of $4.56 per share. The latest price of the firm is $2.12. Our model forecasts the value of Kiora Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.33, current valuation of (10.25 M), and Shares Owned By Insiders of 2.98 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Kiora Pharmaceuticals' valuation include:
Price Book 0.3709 | Enterprise Value | Enterprise Value Ebitda (1.03) | Price Sales 363.7412 | Forward PE 2.4102 |
Undervalued
Today
Please note that Kiora Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Kiora Pharmaceuticals is based on 3 months time horizon. Increasing Kiora Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kiora Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kiora Stock. However, Kiora Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.12 | Real 4.56 | Target 12.0 | Hype 2.11 | Naive 2.14 |
The intrinsic value of Kiora Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kiora Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kiora Pharmaceuticals helps investors to forecast how Kiora stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiora Pharmaceuticals more accurately as focusing exclusively on Kiora Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kiora Pharmaceuticals' intrinsic value based on its ongoing forecasts of Kiora Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kiora Pharmaceuticals' closest peers.
Kiora Pharmaceuticals Cash |
|
Kiora Pharmaceuticals Total Value Analysis
Kiora Pharmaceuticals is now projected to have valuation of (10.25 M) with market capitalization of 8.05 M, debt of 57.17 K, and cash on hands of 2.43 M. The negative valuation of Kiora Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kiora Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(10.25 M) | 8.05 M | 57.17 K | 2.43 M |
Kiora Pharmaceuticals Investor Information
About 20.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded a loss per share of 2.12. The entity last dividend was issued on the 30th of August 2019. The firm had 1:9 split on the 11th of June 2024. Based on the key indicators related to Kiora Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kiora Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Kiora Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kiora Pharmaceuticals has an asset utilization ratio of 43.85 percent. This suggests that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Kiora Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Kiora Pharmaceuticals Profitability Analysis
Based on Kiora Pharmaceuticals' profitability indicators, Kiora Pharmaceuticals is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in March. Profitability indicators assess Kiora Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2013-03-31 | Previous Quarter -2.2 M | Current Value 26.8 K | Quarterly Volatility 2.7 M |
For Kiora Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiora Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiora Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiora Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiora Pharmaceuticals over time as well as its relative position and ranking within its peers.
Kiora Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Kiora Pharmaceuticals is estimated to be -0.5975 with future projections ranging from a low of -0.6875 to a high of -0.5075. Kiora Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -2.12. Please be aware that the consensus of earnings estimates for Kiora Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Kiora Pharmaceuticals Earnings Estimation Breakdown
The calculation of Kiora Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Kiora Pharmaceuticals is estimated to be -0.5975 with the future projection ranging from a low of -0.6875 to a high of -0.5075. Please be aware that this consensus of annual earnings estimates for Kiora Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.69 Lowest | Expected EPS | -0.51 Highest |
Kiora Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Kiora Pharmaceuticals' value are higher than the current market price of the Kiora Pharmaceuticals stock. In this case, investors may conclude that Kiora Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Kiora Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 1 | 52.32% | 0.01 | -0.5975 | -2.12 |
Kiora Pharmaceuticals Ownership Allocation
Roughly 77.1 % of Kiora Pharmaceuticals outstanding shares are held by general public with 2.98 pct. owned by insiders and only 19.92 % by institutional investors.Kiora Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 16 M. Net Income was 3.59 M with loss before overhead, payroll, taxes, and interest of (3.72 M).About Kiora Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Kiora Pharmaceuticals. We calculate exposure to Kiora Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kiora Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 18.4 M | 19.3 M | |
| Pretax Profit Margin | 0.41 | 0.43 | |
| Operating Profit Margin | 0.32 | 0.34 | |
| Net Profit Margin | 0.26 | 0.27 | |
| Gross Profit Margin | (310.94) | (295.40) |
Kiora Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.1 M | |
| Forward Price Earnings | 2.4102 |
Kiora Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Kiora Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kiora we look at many different elements of the entity such as Kiora's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Kiora Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Kiora Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Kiora Pharmaceuticals' worth.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.